
Theseus Pharmaceuticals Investor Relations Material
Latest events

Status Update
Theseus Pharmaceuticals

Q3 2023
17 Nov, 2023

Q2 2023
11 Aug, 2023
Access the full event backlog
Slides, Transcripts, and Reports from 13,000 public companies
Latest reports from Theseus Pharmaceuticals Inc
Access all reports
Theseus Pharmaceuticals Inc., trading under the NASDAQ symbol THRX, is a biopharmaceutical company dedicated to the discovery, development, and commercialization of targeted therapies for cancer patients. The company's leading product candidate is THE-630, a pan-KIT inhibitor aimed at treating gastrointestinal stromal tumors. Additionally, Theseus is developing THE-349, a fourth-generation selective epidermal growth factor receptor inhibitor intended for use in non-small cell lung cancer patients who have developed resistance to first- or later-line osimertinib treatment. The company is headquartered in Cambridge, Massachusetts, and its shares are listed on the Nasdaq.
Latest articles
)
The Fifteenth Generation: A Conversation with Pietro Gussalli Beretta
An interview with Pietro Gussalli Beretta on how Beretta Holding blends 500 years of tradition with global growth, innovation, and long-term vision.
10 Jul 2025
)
Citadel: Relentless Optimization at Global Scale
From a Harvard dorm to global dominance, this is the story of how Ken Griffin created one of the best-performing hedge funds of all time.
4 Jul 2025
)
David A. Ricks: Eli Lilly's Chairman and CEO
David Ricks built a decades-long career at Eli Lilly, now leading the giant company through a defining moment in its long pharmaceutical history.
3 Jul 2025
Ticker symbol
THRX
Country
🇺🇸 United States